← Leaderboards
Paul J Martin
Fred Hutchinson Cancer Research Center
$18,480,958
Attributed
$18,480,958
Total exposure
16
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.6M · FY2005–19$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$18,480,958 · 16
By mechanism
P01$7,408,575 · 6
R01$5,929,231 · 5
P30$4,830,472 · 3
P51$312,680 · 2
Top collaborators
No co-investigators on record.
Most similar at Fred Hutchinson Cancer Research Center
Same institution · by research overlap
- Jeannine S McCune$7,454,702
- George Earl Georges$15,152,269
- Shelly Heimfeld$10,960,565
- Beverly J Torok-Storb$23,179,515
- Ruth D Etzioni$37,666,206
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchMalignant NeoplasmsResearch PersonnelProtocols DocumentationPreventEnrollmentMonitorData CollectionCancer Center Support GrantEnsureResearch SupportMemberMissionReview CommitteeClinical TrialsProgramsBaseCell TransplantationResearch StudyData Base ManagementServicesFundingChronic Graft Versus Host DiseaseResources
Grant awards (80)
Whole Genome Association Analysis of Hematopoietic Cell Transplant (HCT) Outcome$736,012
R01 · FY2019 · HL · contact PI
Clinical Protocol and Data Management$649,499
P30 · FY2019 · CA · contact PI
Protocol Review and Monitoring System$188,397
P30 · FY2019 · CA · contact PI
Clinical Protocol and Data Management$9,134
P30 · FY2019 · CA · contact PI
Protocol Review and Monitoring System$9,134
P30 · FY2019 · CA · contact PI
Protocol Review and Monitoring System$7,408
P30 · FY2019 · CA · contact PI
Clinical Protocol and Data Management$7,408
P30 · FY2019 · CA · contact PI
Protocol Review and Monitoring System$3,703
P30 · FY2019 · CA · contact PI
Clinical Protocol and Data Management$3,703
P30 · FY2019 · CA · contact PI
Clinical Protocol and Data Management$2,890
P30 · FY2019 · CA · contact PI
Protocol Review and Monitoring System$2,890
P30 · FY2019 · CA · contact PI
Whole Genome Association Analysis of Hematopoietic Cell Transplant (HCT) Outcome$741,791
R01 · FY2018 · HL · contact PI
Clinical Protocol and Data Management$649,498
P30 · FY2018 · CA · contact PI
Protocol Review and Monitoring System$188,395
P30 · FY2018 · CA · contact PI
Protocol Review and Monitoring System$9,134
P30 · FY2018 · CA · contact PI
Clinical Protocol and Data Management$9,134
P30 · FY2018 · CA · contact PI
Clinical Protocol and Data Management$8,333
P30 · FY2018 · CA · contact PI
Protocol Review and Monitoring System$8,333
P30 · FY2018 · CA · contact PI
Clinical Protocol and Data Management$7,408
P30 · FY2018 · CA · contact PI
Protocol Review and Monitoring System$7,408
P30 · FY2018 · CA · contact PI
Protocol Review and Monitoring System$2,890
P30 · FY2018 · CA · contact PI
Clinical Protocol and Data Management$2,890
P30 · FY2018 · CA · contact PI
Clinical Protocol and Data Management$1,234
P30 · FY2018 · CA · contact PI
Protocol Review and Monitoring System$1,234
P30 · FY2018 · CA · contact PI
Clinical Protocol and Data Management$614,283
P30 · FY2017 · CA · contact PI
Protocol Review and Monitoring System$208,142
P30 · FY2017 · CA · contact PI
Clinical Protocol and Data Management$649,631
P30 · FY2016 · CA · contact PI
Long-Term Follow-up$291,232
P01 · FY2016 · CA · contact PI
Protocol Review and Monitoring System$188,438
P30 · FY2016 · CA · contact PI
Clinical Protocol and Data Management$667,368
P30 · FY2015 · CA · contact PI
Long-Term Follow-up$291,232
P01 · FY2015 · CA · contact PI
Protocol Review and Monitoring System$193,583
P30 · FY2015 · CA · contact PI
Long-Term Follow-up$282,495
P01 · FY2014 · CA · contact PI
Long-Term Follow-up$273,758
P01 · FY2013 · CA · contact PI
Patient Enrollment, Specimen and Data Management, and Biostatistics$224,944
P01 · FY2013 · AI · contact PI
Long-Term Follow-up$291,232
P01 · FY2012 · CA · contact PI
Patient Enrollment, Specimen and Data Management, and Biostatistics$239,305
P01 · FY2012 · AI · contact PI
Long-Term Follow-up Core$458,329
P01 · FY2011 · CA · contact PI
Prevention and Treatment of Graft-Versus-Host Disease$385,515
P01 · FY2011 · CA · contact PI
Patient Enrollment, Specimen and Data Management, and Biostatistics$267,296
P01 · FY2011 · AI · contact PI
Long-Term Follow-up Core$394,331
P01 · FY2010 · CA · contact PI
Prevention and Treatment of Graft-Versus-Host Disease$290,100
P01 · FY2010 · CA · contact PI
Patient Enrollment, Specimen and Data Management, and Biostatistics$270,674
P01 · FY2010 · AI · contact PI
Core--Long-Term Follow-Up and Chronic GVHD$193,243
P01 · FY2010 · HL · contact PI
EFFICACY OF CD28 ANTIBODY FOR GVHD PREVENTION$155,086
P51 · FY2010 · RR · contact PI
Long-Term Follow-up Core$441,295
P01 · FY2009 · CA · contact PI
Prevention and Treatment of Graft-Versus-Host Disease$325,146
P01 · FY2009 · CA · contact PI
Patient Enrollment, Specimen and Data Management, and Biostatistics$265,496
P01 · FY2009 · AI · contact PI
Core--Long-Term Follow-Up and Chronic GVHD$188,055
P01 · FY2009 · HL · contact PI
EFFICACY OF CD28 ANTIBODY FOR GVHD PREVENTION$157,594
P51 · FY2009 · RR · contact PI
Long-Term Follow-up Core$432,280
P01 · FY2008 · CA · contact PI
Mycophenylate Mofetil for Treatment of Chronic GVHD$382,446
R01 · FY2008 · CA · contact PI
Prevention and Treatment of Graft-Versus-Host Disease$319,177
P01 · FY2008 · CA · contact PI
Core--Long-Term Follow-Up and Chronic GVHD$179,491
P01 · FY2008 · HL · contact PI
Mycophenylate mofetil for treatment of chronic GVHD$361,338
R01 · FY2007 · CA · contact PI
Long-Term Follow-up Core$360,092
P01 · FY2007 · CA · contact PI
Prevention and Treatment of Graft-Versus-Host Disease$266,968
P01 · FY2007 · CA · contact PI
Core--Long-Term Follow-Up and Chronic GVHD$189,423
P01 · FY2007 · HL · contact PI
Mycophenylate mofetil for treatment of chronic GVHD$375,879
R01 · FY2006 · CA · contact PI
Core--Long-Term Follow-Up and Chronic GVHD$183,306
P01 · FY2006 · HL · contact PI
Mycophenylate mofetil for treatment of chronic GVHD$384,925
R01 · FY2005 · CA
Function &Fate of Alloantigen-specific CD8 Cell in GVHD$294,720
R01 · FY2005 · HL
Mycophenylate mofetil for treatment of chronic GVHD$384,925
R01 · FY2004 · CA
Function &Fate of Alloantigen-specific CD8 Cell in GVHD$296,910
R01 · FY2004 · HL
Mycophenylate mofetil for treatment of chronic GVHD$384,925
R01 · FY2003 · CA
Function &Fate of Alloantigen-specific CD8 Cell in GVHD$302,750
R01 · FY2003 · HL
Core--Long term follow-up and chronic GVHD$104,160
P01 · FY2003 · HL
Function &Fate of Alloantigen-specific CD8 Cell in GVHD$302,750
R01 · FY2002 · HL
TEMPORALLY CONTROLLED DEPLETION OF ALLOREACTIVE T CELLS$252,717
R01 · FY2002 · CA
CORE--LONG TERM FOLLOW-UP$0
P01 · FY2002 · CA
CORE--BIOLOGICAL PRODUCTION RESOURCE$0
P30 · FY2002 · CA
CORE--BIOLOGICAL PRODUCTION RESOURCE$0
P30 · FY2002 · CA
Core--Long term follow-up and chronic GVHD$0
P01 · FY2002 · HL
TEMPORALLY CONTROLLED DEPLETION OF ALLOREACTIVE T CELLS$247,120
R01 · FY2001 · CA
CORE--BIOLOGICAL PRODUCTION RESOURCE$188,233
P30 · FY2001 · CA
CORE--BIOLOGICAL PRODUCTION RESOURCE$0
P30 · FY2001 · CA
Core--Long term follow-up and chronic GVHD$0
P01 · FY2001 · HL
CORE--BIOLOGICAL PRODUCTION RESOURCE$340,737
P30 · FY2000 · CA
TEMPORALLY CONTROLLED DEPLETION OF ALLOREACTIVE T CELLS$241,690
R01 · FY2000 · CA
DONOR CD8 EFFECTOR FUNCTION IN MARROW TRANSPLANTATION$238,333
R01 · FY2000 · HL